title: [Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?].
authors.affiliation: Klinik für Kardiologie und Internistische Intensivmedizin Isar Herz Zentrum, Isarkliniken GmbH, München. thorsten.lewalter@isarkliniken.de
authors.forename: T
authors.initials: T
authors.lastname: Lewalter
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D000991:Antithrombins / Q000009:adverse effects / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use; D000069604:Dabigatran; D019317:Evidence-Based Medicine; D065427:Factor Xa Inhibitors; D019983:Guideline Adherence; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D020766:Intracranial Embolism / Q000517:prevention & control*; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D000069552:Rivaroxaban; D020521:Stroke / Q000517:prevention & control*; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D065427:Factor Xa Inhibitors; D009025:Morpholines; D013876:Thiophenes; D015091:beta-Alanine; D000069552:Rivaroxaban; D000069604:Dabigatran